Literature DB >> 9372061

Molecular basis of sickle cell-endothelial cell interactions.

T M Wick1, J R Eckman.   

Abstract

Adherence of sickle erythrocytes to microvascular endothelium is posited to initiate or contribute to sickle cell vaso-occlusive pain episodes. Adherence and occlusion in vivo may depend on hemodynamics interacting with plasma, erythrocyte, and endothelial cell factors. Four receptor-mediated adherence pathways have been described to date: adherence mediated by high molecular weight von Willebrand factor multimers bridging glycoprotein lb-like and integrin receptors on sickle cells and similar receptors on endothelial cells; thrombospondin bridging CD36 on sickle reticulocytes and the alpha v beta 3 integrin on large-vessel endothelial cells or alpha v beta 3 and CD36 on microvascular endothelium; binding of sickle reticulocyte alpha 4 beta 1 receptors to vascular cell adhesion molecule 1 expressed on endothelial cells stimulated by cytokine or double-stranded RNA viruses; and binding of sickle cells to endothelial cell-associated fibronectin via sickle reticulocyte alpha 4 beta 1 activated by phorbol ester or interleukin-8. The significance of these adherence pathways in sickle cell vaso-occlusion is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9372061     DOI: 10.1097/00062752-199603020-00003

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  11 in total

Review 1.  Reticulocytes and reticulocyte enumeration.

Authors:  R S Riley; J M Ben-Ezra; R Goel; A Tidwell
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

Review 2.  Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.

Authors:  Eboni I Lance; James F Casella; Allen D Everett; Emily Barron-Casella
Journal:  Proteomics Clin Appl       Date:  2014-11-06       Impact factor: 3.494

3.  Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph.

Authors:  Sharvil U Sheth; David Palange; Da-Zhong Xu; Dong Wei; Eleonora Feketeova; Qi Lu; Diego C Reino; Xiaofa Qin; Edwin A Deitch
Journal:  J Trauma       Date:  2011-12

Review 4.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

Review 5.  Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

Authors:  Maurice H Dick; Arowa Abdelgadir; Vaishnavi Vijaya Kulkarni; Hamna Akram; Abanti Chatterjee; Sushil Pokhrel; Safeera Khan
Journal:  Cureus       Date:  2022-05-11

6.  An antibody to the lutheran glycoprotein (Lu) recognizing the LU4 blood type variant inhibits cell adhesion to laminin α5.

Authors:  Yamato Kikkawa; Takahiro Miwa; Yukiko Tohara; Takayuki Hamakubo; Motoyoshi Nomizu
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

7.  Heterogeneous red blood cell adhesion and deformability in sickle cell disease.

Authors:  Yunus Alapan; Jane A Little; Umut A Gurkan
Journal:  Sci Rep       Date:  2014-11-24       Impact factor: 4.379

8.  Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.

Authors:  Yunus Alapan; Ceonne Kim; Anima Adhikari; Kayla E Gray; Evren Gurkan-Cavusoglu; Jane A Little; Umut A Gurkan
Journal:  Transl Res       Date:  2016-03-19       Impact factor: 7.012

9.  Dynamic deformability of sickle red blood cells in microphysiological flow.

Authors:  Y Alapan; Y Matsuyama; J A Little; U A Gurkan
Journal:  Technology (Singap World Sci)       Date:  2016-02-19

10.  Characterizing Intracranial Hemodynamics in Sickle Cell Anemia: Impact of Patient-Specific Viscosity.

Authors:  Sara B Keller; Jacob M Bumpus; J Christopher Gatenby; Elizabeth Yang; Adetola A Kassim; Carlton Dampier; John C Gore; Amanda K W Buck
Journal:  Cardiovasc Eng Technol       Date:  2021-07-20       Impact factor: 2.305

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.